CFDE Data Portal | Search RNF14P3

	Label	Description
	RNF14P3 Gene (Entity type)	ENSG00000238109 - RNF14 pseudogene 3
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE93156 idelalisib B cell 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 4 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE168097 epinephrine 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 5 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228357 OGA knockdown 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE221101 GADD45B HOPX overexpression 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GTEx Spleen 20-29 vs 60-69 Up Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Spleen 20-29 vs 50-59 Up Gene Set (Entity type)	A Gene Set from GTEx

RNF14P3

ENSG00000238109 - RNF14 pseudogene 3

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

A Gene Set from LINCS

GSE93156 idelalisib B cell 1 v 0 human dn

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 4 v 7 human dn

A Gene Set from LINCS

GSE168097 epinephrine 3 v 2 human up

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 5 v 0 human dn

A Gene Set from LINCS

GSE228357 OGA knockdown 2 v 0 human up

A Gene Set from LINCS

GSE221101 GADD45B HOPX overexpression 1 v 0 human up

A Gene Set from LINCS

GTEx Spleen 20-29 vs 60-69 Up

A Gene Set from GTEx

GTEx Spleen 20-29 vs 50-59 Up

A Gene Set from GTEx

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.